Trial Profile
Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Temocillin (Primary)
- Indications Urinary tract infections
- Focus Therapeutic Use
- Acronyms TEMO-ESBL
- 01 Jun 2018 Planned End Date changed from 1 Apr 2019 to 1 Sep 2018.
- 01 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Oct 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2019.